Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Chharodi, Ahmedabad-382 481, Gujarat, India.
Fundam Clin Pharmacol. 2011 Feb;25(1):29-47. doi: 10.1111/j.1472-8206.2010.00814.x.
This review shall familiarize the readers with various fundamental aspects of angiogenesis. Angiogenesis is a feature of a limited number of physiological processes like wound healing, ovulation, development of the corpus luteum, embryogenesis, lactating breast, during immune response, and during Inflammation. It is driven by a cocktail of growth factors and pro-angiogenic cytokines and is tempered by an equally diverse group of inhibitors of neovascularization. The properties and biological functions of angiogenic growth factors such as VEGF, FGF-2, nitric oxide, MMP, angiopoietin, TGF-β as well as various inhibitors such as angiostatin, endostatin, thrombospondin, canstatin, DII4, PEDF are discussed in this review with respect to their impact on angiogenic process. In recent years, it has become increasingly evident that excessive, insufficient, or abnormal angiogenesis contributes to the pathogenesis of many more disorders. A long list of disorders is characterized or caused by excessive or insufficient angiogenesis whereas several congenital or inherited diseases are also caused by abnormal vascular remodeling. It may be possible in the future to develop specific anti-angiogenic agents that offer a potential therapy for cancer and angiogenic diseases.
这篇综述将使读者熟悉血管生成的各个基本方面。血管生成是少数生理过程的特征，如伤口愈合、排卵、黄体形成、胚胎发生、哺乳期乳房、免疫反应和炎症。它由一系列生长因子和促血管生成细胞因子驱动，并受到同样多样化的血管生成抑制剂的调节。本文讨论了血管生成生长因子（如 VEGF、FGF-2、一氧化氮、MMP、血管生成素、TGF-β）以及各种抑制剂（如血管抑素、内皮抑素、血栓素、康斯丁、DII4、PEDF）的特性和生物学功能，以及它们对血管生成过程的影响。近年来，越来越明显的是，过度、不足或异常的血管生成会导致许多疾病的发病机制。许多疾病的特征或由过度或不足的血管生成引起，而一些先天性或遗传性疾病也由异常的血管重塑引起。未来可能有可能开发出特异性抗血管生成药物，为癌症和血管生成性疾病提供潜在的治疗方法。
